Despite improvements in emergency treatment, myocardial infarction is often the beginning of a downward spiral leading to congestive heart failure. Other than heart transplantation, current therapeutic means aim at enabling the organism to survive with a heart that is working at a fraction of its original capacity. It is therefore no surprise that cardiac stem cell therapy has raised many hopes. However, neither the ideal source and type of stem cell nor the critical cell number and mode of application have been defined so far. Early reports on myocardial repair by adult bone marrow stem cells from rodent models promoted an unparalleled boost of clinical and experimental cell therapy studies. The phenomenon of stem/progenitor cell-induced angiogenesis in ischemic myocardium has ever since been reproduced by numerous groups in a variety of small and large animal models. Myogenesis, however, is an altogether different matter. Many of the initial clinical studies were fueled by the suggestion that early hematopoietic stem cells have a plasticity high enough to enable cross-lineage differentiation into cells of cardiomyocyte phenotype, but the initial enthusiasm has largely faded. The myogenic potential of stroma cell-derived mesenchymal stem cells is much better documented in animal models, but transfer to the clinical setting faces a variety of obstacles. In clinical pilot trials, we and others have demonstrated the feasibility and safety of administering progenitor cells derived from autologous bone marrow to the myocardium of patients with ischemic heart disease. Clinical efficacy data are still rare, but the few controlled trials that have been completed uniformly show a tendency towards better heart function in cell-treated patients. This review is an attempt to describe the scientific basis for cardiac cell therapy from the point of view of the clinician, focusing on problems that arise with beginning translation into the clinical setting.
INTRODUCTION
cal cord blood (UCB). Understanding of adult/somatic stem cells has been upset by recent experimental data indicating that adult stem cells derived from hematopoi-Stem cells are unspecialized cells that renew themselves for long periods of time and can be induced to etic tissue can give rise to nonhematopoietic cells such as cardiomyocytes, hepatocytes, endothelial, and epithe-become cells with a specialized function. The traditional definition requires the capacity for asymmetric cell divi-lial cells. Initially this was interpreted to represent transdifferentiation of hematopoietic stem cells by crossing sion (i.e., the stem cell divides into one stem cell and one differentiated cell), while a typical progenitor cell lineage boundaries, the so-called "stem cell plasticity" (24) . Alternatively, the existence of nonhematopoietic gives rise to two differentiated daughter cells. Whereas embryonic stem cells are uncommitted and pluripotent stem cells or even more immature multipotent types of stem cells in the various transplanted cell sources, as in their differentiation capability, adult stem cells are believed to differentiate only into specialized cells of the well as the phenomenon of fusion of transplanted cells with resident cells in the damaged organ, has been taken organ or tissue they are derived from. The function of adult stem cells appears to be maintenance and repair of into consideration (6,12). To date the mechanisms underlying adult stem cell-mediated organ regeneration are their tissue of origin. Various types of progenitors and stem cells with myocardial regenerative potential have not clear. In the following, we will discuss the pathophysiologi-been derived from skeletal muscle and myocardium as well as different hematopoietic cell sources, including cal background of ischemic heart failure and the rationale for the employment of adult stem cells to treat myocardial bone marrow (BM), peripheral blood (PB), and umbili-ischemia. We will further highlight information on con-CARDIAC CELL THERAPY tractile muscle-derived regenerative cells as well as adult
The ultimate goal of any cardiac cell therapy apstem cells from hematopoietic tissue to build a basis for proach is the reconstitution of contractile tissue in funca critical discussion of the ongoing clinical trials.
tionally relevant quantities. The neo-tissue must be integrated in the myocardial syncytium, and blood supply to ISCHEMIC HEART DISEASE this tissue must also be secured. Despite a better understanding of its etiology, the Initial reports on experimental cell therapy for myoprevalence of ischemic heart disease remains exceedcardial tissue repair described the implantation of differingly high in industrialized countries and is on the rise entiated cells (i.e., cardiomyocytes) or defined progeniin developing countries. Risk factors for coronary athtor cells (i.e., skeletal myoblasts or EPC) (29, 30, 60) . erosclerosis have long been established, but it remains Due to their ease of isolation, cells from hematopoietic unclear whether there is one unifying mechanism by tissue are currently considered the best available source which atherosclerotic narrowing of the coronary arteries of "true" adult stem cells (18) . Embryonic stem cells develops. In many patients, sudden rupture of the endohave been used experimentally in the context of myocarthelial surface of a localized atherosclerotic plaque leads dial cell therapy, but will not be reviewed here. A very to thrombus formation with acute occlusion of the corointriguing concept is the existence of cardiac stem cells nary vessel. The resulting myocardial ischemia induces that appear to be present in the adult mammal myocarimmediate biochemical changes and loss of myocardial dium (59). Theoretically, such cells could be induced to contractility. Irreversible necrosis of cardiomyocytes proliferate and regenerate the myocardium in situ. Altertakes about 30 min to develop and further extends with natively, they could be isolated, expanded, and turned time for several hours. Thanks to improvements in priinto cardiomyocytes ex vivo, and be reimplanted where mary and secondary prevention as well as therapeutic needed (4,8). The various aspects of myocardial cell interventions, both incidence and mortality of acute therapy have elsewhere been reviewed in great detail myocardial infarction (AMI) recently decreased, but the (9, 41, 45) . Here we will briefly portray various cell types number of individuals suffering AMI is still estimated that are considered to be relevant for clinical application to exceed 1.5 million per year in the US and 2 million today, and discuss some of the problems arising in the per year in Western and Central Europe. Many patients process of rapid bench-to-bedside translation. develop diffuse atherosclerotic disease of the entire coronary artery tree, and repeated episodes of AMI may Contractile (Progenitor) Cells result in severely impaired myocardial contractility and heart failure, often described as "ischemic cardiomyopa-Among the first cells that were implanted in experimental models of myocardial infarction were fetal and thy." The most problematic consequence-besides the clinical symptoms of angina pectoris-is a net loss of neonatal cardiomyocytes. After direct injection into postinfarction scar tissue, they survived, appeared to be contractile tissue. The myocardium mainly consists of terminally differentiated cells without a clinically rele-integrated into the myocardial syncytium as evidenced by formation of intercalated disks and expression of spe-vant potential for regeneration, although the existence of cardiac stem cells has recently been indicated. Hence, cific gap-junction proteins, and led to improvement of myocardial contractility (25). Even though the initial re-large numbers of cardiomyocytes that were subject to necrotic or apoptotic cell death cannot sufficiently be ports were promising, cardiomyocyte transplantation is unlikely to reach clinical significance soon. Neonatal ro-replaced by new contractile cells. Instead, remodeling processes ultimately lead to diffuse interstitial myocar-dent cardiomyocytes can be isolated and cultivated, but adult cardiomyocytes in higher mammals have virtually dial fibrosis or formation of a transmural fibrous scar. Without invasive treatment, survival of patients with no capacity for proliferation in cell culture. Theoretically, allogenic or xenogenic cardiomyocytes could be myocardial infarction and considerably reduced left ventricular contractility [e.g., left ventricular ejection frac-obtained from donors, but would be subject to rejection, unless immunosuppression would be induced as in any tion (LVEF) <30%] is less than 40% after 5 years, which illustrates the urgent need for novel therapeutic other organ transplant patient. Moreover, transplanted cardiomyocytes are as susceptible to ischemia as the na-measures. Surgical or interventional restoration of blood supply to ischemic myocardium effectively treats an-tive cardiomyocytes. Implanted in ischemic myocardium, they are therefore prone to succumb to tissue hypoxia gina, prevents myocardial infarction, improves function of the remaining viable myocardium, but viability and just as the native host cells did. Cardiomyocytes spontaneously produce action potentials, albeit slowly. In fact, function of necrotic myocardium cannot be restored with current therapeutic means.
transplanted cardiomyocytes have been shown to act as pacemakers after implantation in dog hearts once the na-myocardium; instead they appear to form distinct islets in postinfarct tissue. Cx43 expression in transplanted tive conduction system was destroyed (50) .
In contrast, smooth muscle cells do not contract spon-myoblasts has been described in several animal models, but has not been detected in patients who underwent my-taneously in vitro or after implantation in the heart. They can be isolated from intestine, blood vessel wall, or gen-oblast injection and postmortem histology studies.
In a careful study of myoblast transplantation in itourinary organs, and may readily be expanded in cell culture. Their potential usefulness for restoration of con-mice, Rubart et al. found that the majority of the intramyocardial myoblasts/myotubes are functionally iso-tractile tissue following AMI has been demonstrated in rodent models (26) , but they are currently not as inten-lated from the surrounding myocardium, and suggested that the remaining cells connect with host cardiomyo-sively studied as other cell types.
The largest body of knowledge has most likely been cytes as a result of cell fusion (49). Their observations might not only explain the conflicting results of other collected regarding skeletal myoblasts. These so-called "satellite cells" reside in the periphery of skeletal muscle studies, but also provide an explanation of a significant clinical problem: the durations of calcium transients re-fibers and serve to regenerate skeletal muscle tissue following injuries. Skeletal myoblasts can be readily iso-corded from intramyocardial skeletal myoblasts were heterogeneous compared with those in neighboring host lated from a small muscle biopsy; in humans the thigh musculature is commonly used. The isolation process in-cardiomyocytes, which may interfere with the propagation of excitation across the ventricular myocardium and volves mechanic destruction and enzymatic digestion of myofibers, and the myoblasts are collected and enriched pose the heart at risk of ventricular arrhythmia. Rhythm disturbances have indeed been observed in several pa-by filtration and plating. No specific surface markerbased cell selection is necessary. There is usually some tients who underwent skeletal myoblast implantation. Whereas the very first patient who underwent myoblast fibroblast contamination, which can be sufficiently controlled by frequent culture replating, and purity of the implantation together with a coronary artery bypass operation (CABG) in a pioneering undertaking by Men-final product should exceed 80%. Myoblasts have a robust proliferation capacity and multiply in high-serum asche and colleagues had an uneventful postoperative course (31) , several other patients developed life-threat-concentration for numerous passages without changes in phenotype. Once the serum concentration in the medium ening ventricular arrhythmia a few days after the procedure. Surgical patients were still under close observation is lowered, they rapidly differentiate and fuse to form multinucleated myotubes. and could be treated, but elsewhere patients had undergone transcatheter myoblast implantation with early dis-Besides their intrinsically preprogrammed differentiation in a myocyte phenotype, their most intriguing qual-charge from the hospital and could not be saved. Therefore, at least in well-structured trials, clinical ity is resistance to hypoxia, and it has been assumed that myoblasts are able to survive in ischemic myocardium myoblast implantation for heart failure is currently limited to patients who have an automatic defibrillator de-better and longer than cardiomyocytes. Doubt remains, however, as to their ability to functionally integrate into vice implanted. As to the efficacy of myoblast implantation, numerous small-and large-animal studies have the myocardial syncytium (i.e., to express cardiac-specific connexins and form functioning gap junctions with sur-shown a significant improvement of left ventricular contractility. Results of the early clinical pilot trails were rounding viable cardiomyocytes). In principle, undifferentiated myoblasts can express connexin 43 (Cx43), the also encouraging, but results of large-scale controlled clinical trials are not yet available. predominant gap-junction protein in ventricular myocardium, and at least some of the myoblasts appear to be Marrow, Blood, and Cord Blood Cells able to form functioning cell-cell communications with cocultured cardiomyocytes in vitro (46). Once they have Blood and bone are attractive, readily accessible sources of stem cells. These cell reservoirs harbor vari-differentiated and formed myotubes in conventional 2D culture, the Cx43 expression is markedly downregulated ous populations of candidate regenerative cells including hematopoietic progenitor cells (HPC) (30) and hemato-but may persist to some degree.
On the other hand, when myoblasts are grown and poietic stem cells (HSC), endothelial progenitor cells (EPC) (29) , mesenchymal stem cells (MSC) (18, 45, 60) , differentiate in 3D culture under mechanical stimulation such as longitudinal strain, Cx43 expression is preserved and multipotent adult progenitor cells (MAPC) (9,41). In the context of cardiac cell therapy, the term "adult or even upregulated. The situation in vivo after implantation in infarcted myocardium is naturally more diffi-stem cells" usually refers to the application of mixed cell populations obtained from marrow, peripheral blood, cult to assess. Many reports indicated that skeletal myotubes are not morphologically integrated in the host or cord blood. Other sources of cells with the capacity for asymmetric division and plasticity such as fatty tis-ment in favor of positive selection to enrich adult SC for clinical use. sue or pancreas have, so far, only occasionally been used in myocardial regeneration attempts. Contradictory find-In Vivo Myocardial Regeneration by Adult Stem Cells ings regarding the regenerative potency of these cells are considered to be, at least in part, due to the heteroge-Ideally, a stem cell that has been implanted into infarcted myocardium would give rise to new blood ves-neity of stem cells present in different sources and preparations.
sels and new contractile cells (i.e., angiogenesis and myogenesis). Proliferation and differentiation would be Within bone marrow, at least two distinct populations of progenitor and stem cells have so far been clearly guided by local humoral and/or cellular control mechanisms, and no neoplastic growth or differentiation in un-recognized. These are (i) CD34 + /45 + /133 + HPC including a small fraction of HSC as the traditional source wanted noncardiac cell types would occur. So far, neither the ideal source and type of SC nor the critical cell of hematopoietic progeny, and (ii) CD34 − /45 − /133 − MSC with the capacity to renew marrow stroma, support he-number and mode of application have been defined. In 2001, two experimental studies of myocardial re-matopoiesis, and to differentiate into various mesodermal cell types including connective tissue (chondro-pair by adult stem cells from hematopoietic sources after experimental myocardial infarction promoted an unpar-cytes, osteocytes), adipocytes, and myocytes (43, 44) . The phenotype of in vitro cultured MSC shows a typical alleled boost of clinical and experimental regenerative SC therapy studies. They also mirror the variety of adult combination of marker molecules CD73 (SH3, SH4), CD90 (Thy1), and CD105 (SH2) with a lack of the he-SC used for myocardial repair. Kocher (38) .
A minute subpopulation of cells that copurify with Lin NEG /c-Kit + SC or cytokine-induced SC mobilization (35,36). MSC has been originally described as mesodermal progenitor cell and, due to the wide spectrum of differentia-Many of the initial clinical pilot trials were fueled by the suggestion that early hematopoietic stem cells have tion, renamed as MAPC (47) . These CD34 − /133 + /Flk1 + cells have been postulated to comprise the principle en-a plasticity high enough to enable differentiation into contractile cells of cardiomyocyte phenotype. In fact, dothelial progenitor in human postnatal BM (48). Human MAPC can differentiate into adipocytes, osteo-such cells were considered to be able to truly regenerate infarcted myocardium by promoting both neoangiogen-blasts, EC, and hepatocytes in vitro and, after injection into the tibialis anterior muscle of NOD/SCID mice in esis and neomyogenesis. The initial enthusiasm, however, has largely faded. While in situ neoangiogenesis vivo, into myocytes (33).
Endothelial cells can definitively be derived from induction by hematopoietic cells, associated with functional improvements, is consistently observed, it proved bone marrow (27) but a conclusive description of an endothelial stem cell in adult bone marrow is still a matter difficult to find corroborating evidence for true cardiomyocyte differentiation. In fact, two independent groups of debate. CD133 + /VEGFR2 + BM-derived cells are currently the most widely used functional EPC (60) . Puta-reported early in 2004 that they did not detect any meaningful evidence of cardiomyocyte differentiation of tive BM-derived progenitors of endothelial cells have been originally recovered from normal peripheral blood hematopietic stem cells in mouse models that were designed to confirm the earlier findings (3, 34) . as CD34 + /45 + cells (1) . The relation between these cells and circulating endothelial cells could not be clarified
In contrast, the myogenic potential of stroma cellderived mesenchymal stem cells is much better docu-so far (54) .
Various types of cells related to the endothelial lin-mented. Several years ago, Wakitani et al. reported the in vitro development of myogenic cells from rat bone eage have thus far been described in most hematopoietic and nonhematopoietic tissues. The differences in fre-marrow mesenchymal stem cells exposed to the DNA demethylating agent 5-azacytidine (62), and Makino et quency, phenotype, and function of these endothelial lineage cells clearly need to be analyzed in greater detail.
al. isolated a cardiomyogenic cell line from murine bone marrow stromal cells that were treated with 5-azacyti-The reactivity of several of these cell types with CD133 and the coexpression of CD133 on the greater part of dine and screened for spontaneous beating (28) . Those cells connected with adjoining cells, formed myotube-CD34 + HPC and HSC have been taken as a strong argu-STEM CELLS FOR ISCHEMIC HEART DISEASE S51 like structures, and beat spontaneously and synchro-bly multifactorial. First of all, the ischemic myocardium is obviously a hostile environment, due to local hypoxia, nously. They expressed various cardiomyocyte-specific proteins, had a cardiomyocyte-like ultrastructure, and acidosis, lack of substrates, and accumulation of metabolites. Skeletal myoblasts are known to be quite resistant generated several types of sinus node-like and ventricular cell-like action potentials.
to ischemia, but little is known about the energy requirements of hematopoietic or mesenchymal stem cells. Sec-When isogenic marrow stromal cells are implanted in rat hearts, they appear to become integrated in cardiac ond, necrotic myocardium is subject to infiltration with phagocytic cells that remove cell debris and initiate the myofibers, assume the histologic phenotype of cardiomyocytes, express connexins, and form gap junctions scarring process. Even though the stem/progenitor cells used clinically are autologous, many are probably lost with native cardiomyocytes (7,63). Again, pretreatment with 5-azacytidine is believed to facilitate differentiation in this "clean-up" process. Third, the mechanic forces that are present in the myocardium may play a role. towards a cardiomyocyte phenotype in vivo (5). Human mesenchymal stem cells derived from the marrow of Transmural pressure is high during systole, and there are shear forces between contracting myofibers and layers. volunteers have also been injected in hearts of immunodeficient mice, and again it was observed that they as-Again, a skeletal myoblast might be able to tolerate this, but a marrow cell is certainly not well equipped to with-sume cardiomyocyte morphology and express various cardiomyocyte-specific proteins (57) . stand such stress. Fortunately, the rate of cell death can be slowed by targeted manipulation of the cells to be Taken together, there is quite convincing evidence that mesenchymal stem cells derived from marrow injected. Transfection of marrow stromal cells with a gene encoding for the antiapototic protein AKT has been stroma may assume a myocyte-like phenotype under certain conditions, while hematopoietic stem and pro-shown to greatly improve cell survival and regenerative capacity upon injection in infarcted myocardium. Pre-genitor cell types are primarily involved in angiogenic processes. Nevertheless, numerous questions remain to treatment of endothelial progenitor cells with eNOSenhancing substances also appears to have a beneficial be answered before cell therapy for neovascularization of ischemic myocardium can become clinical routine.
conditioning effect. Simple hypoxic preconditioning prior to cell injection might also help, because it has First, is the angiogenic potential of human cells sufficient for relevant neovascularization of ischemic myo-been shown to activate both antiapoptotic and NO-related signaling pathways. cardial tissue? Second, what are the best surface markers of human adult stem cells with angiogenic potential? DETERMINING FUNCTIONAL EFFECTS Third, how are such cells best delivered to ischemic myocardium? Fourth, what is the molecular mechanism To the clinician, the functional effects of myocardial cell therapy matter so much more than histologic evi-of stem cell endothelial differentiation? Fifth, are there risks of cell-induced neovascularization that outweigh dence of neoangiogenesis or neomyogenesis. The reliability of left ventricular function measurements in ex-the potential benefit? Finally, can the natural angiogenesis-inducing capacity of adult stem cells, which is obvi-perimental models depends both on the animal model and on the method used. Much of the basic experimental ously not sufficient in many situations, be further augmented?
work on cell therapy for myocardial regeneration has been done in mouse models. The main reasons for that CELL SURVIVAL are the availability of immunodeficient mice (SCID mice) that allow for the use of human cell transplants When cells are injected into ischemic myocardium, it is likely that most of them do not survive. The cell with immunologic response, the use of GFP, lac-Z, or otherwise labeled cells from genetically modified ani-preparation process is usually well tolerated. Skeletal myoblasts or other ex vivo expanded cells, as well as mals, and the ready availability of antibodies and nucleic acid probes for detailed expression analysis in situ. The processed primary cells, normally have viability rates higher than 90%. It is often argued that injection of cell problem, however, is the functional analysis. Echocardiographic as well as magnetic resonance imaging of suspension through a needle or a catheter significantly compromises cell viability. In our experience, this is not mouse hearts are indeed possible, but given the tiny dimensions and tremendously high heart rate, reliable de-the case. Even injection through a long cardiac catheterization device has very little effect on cell survival. termination requires highly experienced investigators. The availability of athymic rats allows for xenogenic Once the cells have entered the myocardial interstitium, however, many of them appear to succumb to necrotic transplantation of human cell populations without Tcell-mediated acute rejection, and functional studies are or apoptotic death. Its magnitude is difficult to determine, but the suggested survival rate over days or weeks much easier. Serial echocardiographic analysis of global LV function and dimensions can be performed with ranges between 0.1% and 10%. The causality is proba-good reproducibility. Moreover, cardiac catheterization given cell population, as well as the host-related issues such as the infarct size or the interval between myocar-is feasible, and by using a multielectrode electromagnetic conductance catheter supplied with a pressure trans-dial infarction and cell treatment. ducer, LV pressure-volume curves can be recorded. Those allow for detailed functional analysis of myocar-CLINICAL APPLICATION dial contractility and relaxation properties.
Skeletal Myoblasts
The rabbit as a model for myocardial cell transfer experiments is being used quite rarely. There is no clear Translation of experimental cell therapy approaches for myocardial regeneration into the clinical setting has advantage with respect to functional analysis compared with the rat, and the problems with antibodies and other just begun. Whether the first clinical pilot trials were initiated too early remains subject to very controversial tools for expression profiling and histology are notorious. Thus, truly reliable analysis of myocardial function debate. The earliest clinical application was reported by Menasche and colleagues (31) . A patient with signifi-following cell therapy requires the use of a large-animal model (i.e. porcine, canine, or ovine). Here, both echo-cantly reduced LV contractility following myocardial infarction had to undergo coronary artery bypass grafting cardiography and MR imaging allow for serial studies of global as well as regional myocardial contractility in (CABG) to optimize myocardial blood supply. Two weeks before, a muscle sample was obtained from the the specific area of interest. In acute experiments or setups with chronic instrumentation, very reliable sonomi-thigh, and skeletal myoblasts were cultivated and grown for several passages. During the bypass operation, these crometry data can be obtained following cardiac implantation of ultrasound crystals. Scintigraphic perfusion cells were directly injected into the infarcted myocardium. The patient tolerated the procedure well, and a scans and coronary angiography can be performed. A major disadvantage of many large-animal models is the distinct improvement of wall thickening and motion in the area of cell injection was noted postoperatively. This deficiency of antibodies against stem cell surface markers, and the inevitable immunresponse when xenogic procedure has been repeated worldwide ever since, and the reports quite uniformly describe a mild improvement (i.e., human) cells are used.
The baseline result of most of the published work is in contractility. Analogous to the experimental experience, however, the myofibers that originated from the that there is some improvement of global and-if appropriate-regional contractility following adult stem/pro-transferred myoblasts appear to survive in the infarct tissue but do not fully integrate into the myocardial syncy-genitor cell implantation in ischemic myocardium. This has been described for skeletal myoblasts, unfractionated tium (see above). The CABG operation represents a unique opportunity to directly access the infarcted myo-mononuclear bone marrow cells, stroma cell-derived cell lines, and cells selected using markers of hematopoietic cardium, but at the same time does it conceal the effects of the cell therapy. Analysis of regional contractility stem cells or endothelial progenitor cells. The improvement of global left ventricular contractility is usually in may give some hints regarding the cell-induced functional improvement, but, inevitably, there is always the range of 5% to 20%, and the size of the infarct area is somewhat smaller on histology than in untreated ani-some overlap with the effects of myocardial revascularization. mals. In several small animal studies, a reduction of postinfarct mortality has also been observed. One partic-Recently, procedures have been developed that enable the cardiologist to deliver cells directly to the myo-ularly important lesson learned from large-animal experiments is the notion that one should aim at injecting cells cardium as a stand-alone treatment. By using a novel cardiac catheterization device, the infarcted myocardium that work primarily via angiogenesis induction into the infarct border zone, rather than in the center of the in-can be quite precisely located based on its electrophysiologic properties. A map of the endocardial surface of the farct area. Only by doing so a relevant improvement of myocardial contractility and perfusion is likely to be in-LV myocardium is then constructed that clearly depicts the localization of the infarct tissue. A needle is ad-duced (13). When primarily contractile cells (i.e., myoblasts) are used in sufficiently vascularized tissue, this vanced into through the endocardial layer into the myocardium at a preset depth, and the cell suspension is in-may be less important. To date, no clear advantage of one cell type over another can be seen. Several studies jected. This procedure has been performed in patients with severely impaired LV function, and, again, a mild attempted a direct comparison between two or more different cell populations (i.e., skeletal myoblasts vs. bone improvement of LV contractility was noted, together with some relief of the symptoms of ischemic heart fail-marrow cell, or marrow cells vs. endothelial progenitor cells) but the data are not conclusive yet. The same is to ure. The myoblast injection, however, appears to result in a transient period of electrical instability a few days be said regarding the dose-response relationship of a after the injection, which repeatedly leads to sustained chest pain and ECG shows signs of myocardial ischemia. Lab tests indicate the onset of myocardial necrosis ventricular arrhythmia (see above). and liberation of cardiomyocyte-specific intracellular Bone Marrow Cells proteins (i.e., CK-MB, troponin) following loss of cell membrane integrity. If possible, the blocked coronary While clinical skeletal myoblast transfer is mainly limited to patients with chronic heart failure, cell therapy artery is immediately reopened by emergency catheterization, balloon dilation, and stent placement. The extent with bone marrow-or blood-derived cells may evolve in a novel treatment option for both chronic ischemic heart of myocardial necrosis and thus the impairment in contractility largely depends on the time that has passed un-disease and acute myocardial infarction. In either situation, the angiogenic potential of certain adult stem/pro-til the infarct vessel was reopened. There is no way to predict the ultimate infarct size in a given patient. Ide-genitor cell types is probably the key to functional improvements, whereas true neomyogenesis is, at present, ally, cardiomyocyte necrosis is completely prevented because the coronary artery has been quickly reopened. rather unlikely. Around 2001 a number of clinical trials were initiated, and among the first published was the Analogous to the chronically hibernating myocardium, acutely ischemic cardiomyocytes can still be vital but work by Hamano et al. (14) , who injected bone marrow mononuclear cells intramyocardially during a CABG have temporarily lost much of their capacity for contractile work (myocardial stunning). Tissue infiltration with operation, Tse et al. (58) , who used a catheter-based system for direct intramyocardial delivery of mononuclear inflammatory cells is beginning, but fibrous scarring has not yet occurred. In this situation, direct injection of cell cells, and our own group, who injected a purified population of AC133++ bone marrow cells, again in conjunc-suspension into the weakened myocardium is prohibitive, but infusion of stem/progenitor cells into the re-tion with a CABG operation (54) . Several other groups have reported similar studies (10, 11, 42) . opened coronary artery is currently being evaluated. So far, mainly bone marrow mononuclear cell preparations What these trials have in common is that patients with chronic ischemic heart disease have been treated.
have been used in such trials. A few days after the onset of myocardial infarction, a second cardiac catheteriza-The most recent myocardial infarction in those patients usually dates back several weeks, months, or even years. tion is performed and the cell suspension is injected into the infarct vessel while blood is temporarily interrupted In the infarcted or chronically ischemic myocardium, a substantial net loss of contractile tissue mass has oc-by balloon inflation. Pilot studies have demonstrated feasibility and safety of this approach, and controlled curred, increased collagen deposition has led to a more or less pronounced, diffuse, or localized scar formation, efficacy trials are currently on the way. In one of the first of those trails, there was a difference in LV ejection and blood supply to the myocardium remains impaired although there may have been some collateral vessel fraction of 6% at 6 months follow-up between 30 patients who received intracoronary cell injection and 30 growth. Usually, the ischemic myocardium in those patients is not a complete transmural fibrous scar, which patients who only had standard infarct treatment. On average, LVEF improved by 6.7% in cell-treated patients would eventually progress into a left ventricular aneurysm, but still vital cardiomyocytes are dispersed within compared with immediately after myocardial infarction, whereas LVEF in control patients remained largely un-the fibrous network. Theoretically, such "hibernating" cardiomyocytes can be rerecruited for contractile work changed (64) . Other clinical trials based on the same principle are currently being undertaken, but it is too once sufficient supply of oxygen and nutrients has been reestablished, and stem/progenitor cell-induced growth early to make a definitive judgment about long-term functional efficacy and possible side effects. of microvessels in the infarct border zone may thus translate into improved myocardial contractility. Never-Stem Cell Mobilization theless, it should be kept in mind that the chances to resuscitate hibernating cells in a functionally relevant Another, fundamentally different, approach aims at circumventing any invasive procedure for cell delivery fashion are likely to decrease with time. The longer the interval between myocardial infarction and cell treat-while minimizing the interval between the onset of myocardial infarction and cell therapy by mobilizing marrow ment is, the smaller the chance to achieve a beneficial effect becomes. This notion, however, is largely intu-cells using cytokines such as granulocyte stimulating factor (G-CSF). The idea is that stem/progenitor cells itive, and presently not supported by clear-cut data.
The situation in acute myocardial infarction studies mobilized from marrow will be attracted to the ischemic heart and initiate regeneration events or at least modu-is fundamentally different. Here, the onset of myocardial ischemia is usually between several hours and a few late remodeling processes. The physiologic equivalent of such reasoning may be the mobilization of EPC in days ago. Typically, a patient is admitted with acute 
